These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 35357654)

  • 1. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
    De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
    Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Syndecan-1 is a novel molecular marker for triple negative inflammatory breast cancer and modulates the cancer stem cell phenotype via the IL-6/STAT3, Notch and EGFR signaling pathways.
    Ibrahim SA; Gadalla R; El-Ghonaimy EA; Samir O; Mohamed HT; Hassan H; Greve B; El-Shinawi M; Mohamed MM; Götte M
    Mol Cancer; 2017 Mar; 16(1):57. PubMed ID: 28270211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer.
    Serrano-Oviedo L; Nuncia-Cantarero M; Morcillo-Garcia S; Nieto-Jimenez C; Burgos M; Corrales-Sanchez V; Perez-Peña J; Győrffy B; Ocaña A; Galán-Moya EM
    Cell Oncol (Dordr); 2020 Jun; 43(3):431-444. PubMed ID: 32166583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
    Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
    Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulated SCUBE2 expression in breast cancer stem cells enhances triple negative breast cancer aggression through modulation of notch signaling and epithelial-to-mesenchymal transition.
    Chen JH; Kuo KT; Bamodu OA; Lin YC; Yang RB; Yeh CT; Chao TY
    Exp Cell Res; 2018 Sep; 370(2):444-453. PubMed ID: 29981340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KDM1A inhibition is effective in reducing stemness and treating triple negative breast cancer.
    Zhou M; Venkata PP; Viswanadhapalli S; Palacios B; Alejo S; Chen Y; He Y; Pratap UP; Liu J; Zou Y; Lai Z; Suzuki T; Brenner AJ; Tekmal RR; Vadlamudi RK; Sareddy GR
    Breast Cancer Res Treat; 2021 Jan; 185(2):343-357. PubMed ID: 33057995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOTCH4 maintains quiescent mesenchymal-like breast cancer stem cells via transcriptionally activating SLUG and GAS1 in triple-negative breast cancer.
    Zhou L; Wang D; Sheng D; Xu J; Chen W; Qin Y; Du R; Yang X; He X; Xie N; Liu S; Zhang L
    Theranostics; 2020; 10(5):2405-2421. PubMed ID: 32104513
    [No Abstract]   [Full Text] [Related]  

  • 10. Dual inhibition of Wnt and Yes-associated protein signaling retards the growth of triple-negative breast cancer in both mesenchymal and epithelial states.
    Sulaiman A; McGarry S; Li L; Jia D; Ooi S; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Gadde S; Li X; Wang L
    Mol Oncol; 2018 Apr; 12(4):423-440. PubMed ID: 29316250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A; Kaur P; Lang JE
    BMC Cancer; 2020 Nov; 20(1):1076. PubMed ID: 33167919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. JARID2 activation by NFYA promotes stemness of triple-negative breast cancer cells through the PI3K/AKT pathway.
    Li J; Zhang X; Liu X; Ma X; Wang Y; Liu Y
    Expert Rev Anticancer Ther; 2024 Oct; 24(10):1029-1040. PubMed ID: 39254227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-4319 Suppress the Malignancy of Triple-Negative Breast Cancer by Regulating Self-Renewal and Tumorigenesis of Stem Cells.
    Chu J; Li Y; Fan X; Ma J; Li J; Lu G; Zhang Y; Huang Y; Li W; Huang X; Fu Z; Yin Y; Yuan H
    Cell Physiol Biochem; 2018; 48(2):593-604. PubMed ID: 30021199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Triple-Negative Breast Cancer with TORC1/2 Inhibitors Sustains a Drug-Resistant and Notch-Dependent Cancer Stem Cell Population.
    Bhola NE; Jansen VM; Koch JP; Li H; Formisano L; Williams JA; Grandis JR; Arteaga CL
    Cancer Res; 2016 Jan; 76(2):440-52. PubMed ID: 26676751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selectively Targeting Breast Cancer Stem Cells by 8-Quinolinol and Niclosamide.
    Cámara-Sánchez P; Díaz-Riascos ZV; García-Aranda N; Gener P; Seras-Franzoso J; Giani-Alonso M; Royo M; Vázquez E; Schwartz S; Abasolo I
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Notch Signaling Regulates Mitochondrial Metabolism and NF-κB Activity in Triple-Negative Breast Cancer Cells via IKKα-Dependent Non-canonical Pathways.
    Hossain F; Sorrentino C; Ucar DA; Peng Y; Matossian M; Wyczechowska D; Crabtree J; Zabaleta J; Morello S; Del Valle L; Burow M; Collins-Burow B; Pannuti A; Minter LM; Golde TE; Osborne BA; Miele L
    Front Oncol; 2018; 8():575. PubMed ID: 30564555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long non-coding RNA NEAT1 confers oncogenic role in triple-negative breast cancer through modulating chemoresistance and cancer stemness.
    Shin VY; Chen J; Cheuk IW; Siu MT; Ho CW; Wang X; Jin H; Kwong A
    Cell Death Dis; 2019 Mar; 10(4):270. PubMed ID: 30894512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity.
    Liu Q; Chung S; Murata MM; Han B; Gao B; Zhang M; Lee TY; Chirshev E; Unternaehrer J; Tanaka H; Giuliano AE; Cui Y; Cui X
    Int J Biol Sci; 2022; 18(10):4203-4218. PubMed ID: 35844787
    [No Abstract]   [Full Text] [Related]  

  • 19. Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.
    Liu H; Yan R; Xiao Z; Huang X; Yao J; Liu J; An G; Ge Y
    Breast Cancer Res; 2023 Apr; 25(1):43. PubMed ID: 37069669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA CCAT2 promotes oncogenesis in triple-negative breast cancer by regulating stemness of cancer cells.
    Xu Z; Liu C; Zhao Q; Lü J; Ding X; Luo A; He J; Wang G; Li Y; Cai Z; Wang Z; Liu J; Liu S; Li W; Yu Z
    Pharmacol Res; 2020 Feb; 152():104628. PubMed ID: 31904506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.